文献速递基础与转化研究新药、器械与细胞基因治疗研发

靶向BAFF-R的CAR T细胞可克服B细胞恶性肿瘤中的CD19抗原丢失

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.
PubMed 文献 · Sci Transl Med · 2019-01-01

研究开发了靶向B细胞活化因子受体(BAFF-R)的人源化二代CAR T细胞,在体外对人淋巴瘤和急性淋巴细胞白血病(ALL)细胞系有细胞毒性。单次过继转移可清除10天预建立的肿瘤异种移植模型,并对CD19表达缺陷的异种移植瘤保持疗效。四例CD19导向治疗后CD19抗原丢失的复发原发ALL仍保留BAFF-R表达并能激活BAFF-R-CAR T细胞;BAFF-R-CAR T细胞在体内对另一例CD19抗原丢失的原发患者来源异种移植(PDX)也显示抗肿瘤效应。

要点

  • 靶向BAFF-R的人源化二代CAR T细胞对淋巴瘤和ALL细胞系有细胞毒性。
  • 单次过继转移BAFF-R-CAR T细胞可清除10天预建立的肿瘤异种移植瘤。
  • BAFF-R-CAR T细胞对CD19表达缺陷的异种移植瘤保持疗效,包括CD19阳性淋巴瘤背景中的CD19阴性变异。

核心结论

  • BAFF-R适合作为CAR T细胞治疗靶点,靶向BAFF-R可能防止CD19抗原丢失变异的出现。

研究设计与样本

  • 研究开发了靶向BAFF-R的人源化二代CAR T细胞,并在人淋巴瘤和急性淋巴细胞白血病(ALL)细胞系、肿瘤异种移植模型、CD19抗原丢失的原发ALL及原发患者来源异种移植(PDX)中评价其效果。

主要发现

  • BAFF-R-CAR T细胞对人淋巴瘤和ALL细胞系显示细胞毒性。
  • 单次过继转移BAFF-R-CAR T细胞可清除10天预建立的肿瘤异种移植瘤。
  • BAFF-R-CAR T细胞对CD19表达缺陷的异种移植瘤保持疗效,包括CD19阳性淋巴瘤细胞背景中的CD19阴性变异。
  • 四例CD19导向治疗后CD19抗原丢失的复发原发ALL仍保留BAFF-R表达,并能激活BAFF-R-CAR T细胞而非CD19-CAR T细胞。
  • BAFF-R-CAR T细胞而非CD19-CAR T细胞在体内对另一例CD19抗原丢失的原发患者来源异种移植(PDX)显示抗肿瘤效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CAR T cells targeting CD19 provide promising options for treatment of B cell malignancies. However, tumor relapse from antigen loss can limit efficacy. We developed humanized, second-generation CAR T cells against another B cell-specific marker, B cell activating factor receptor (BAFF-R), which demonstrated cytotoxicity against human lymphoma and acute lymphoblastic leukemia (ALL) lines. Adoptively transferred BAFF-R-CAR T cells eradicated 10-day preestablished tumor xenografts after a single treatment and retained efficacy against xenografts deficient in CD19 expression, including CD19-negative variants within a background of CD19-positive lymphoma cells. Four relapsed, primary ALLs with CD19 antigen loss obtained after CD19-directed therapy retained BAFF-R expression and activated BAFF-R-CAR, but not CD19-CAR, T cells. BAFF-R-CAR, but not CD19-CAR, T cells also demonstrated antitumor effects against an additional CD19 antigen loss primary patient-derived xenograft (PDX) in vivo. BAFF-R is amenable to CAR T cell therapy, and its targeting may prevent emergence of CD19 antigen loss variants.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Qin H, Dong Z, Wang X, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019. PMID: 31554741. doi:10.1126/scitranslmed.aaw9414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。